Mañas A, Casas F, Ciria J P, López C, Sáez J, Palacios A, de las Heras M, Porto C, Sánchez E, Martín C, Esco R, Veiras C, Martínez J C, Márquez M, Ramos A, Calvo F, Fuertes J, Andreu F J, Contreras J, Pérez L, Romero J, Vayreda J, Victoria C
Jefe del Servicio de Oncología Radioterápica, Hospital Universitario La Paz, Madrid, Spain.
Clin Transl Oncol. 2008 May;10(5):281-7. doi: 10.1007/s12094-008-0198-5.
To assess the effectiveness of a single dose of radio therapy (8 Gy vs. 6 Gy) plus zoledronic acid in cancer patients with bone metastases in treating pain; quality of life, time to onset of skeletal events and functional status.
A total of 139 patients from 22 Spanish hospitals were randomly assigned to: Group A, administered a single dose of 8 Gy+zoledronic acid (4 mg iv, in 15-min infusions), and Group B, administered a single dose of 6 Gy+zoledronic acid (4 mg iv, in 15-min infusions). The main variable was pain, which was assessed with the Visual Analogue Pain Scale (VAS) in supine, seated and standing positions.
There was a total of 118 patients for intention to treat (n=67 in Group A and n=51 in Group B). The most frequent primary neoplasms were the lung (29.66%), prostate (22.03%) and breast (21.19%). Sixty patients were analysed per protocol, n=34 in group A and n=26 in group B. Improvements were observed in the VAS scores for pain in all three positions. The mean time to onset of the event was greater (p=0.0211) in Group A than in Group B (122 vs. 81.62 days). Functional status improved in Group A, and quality of life improved in both groups.
The two groups achieved similar levels of pain control in supine, seated and standing positions. Quality of life also improved in both groups. However, the higher dose (8 Gy dose) in combination with zoledronic acid is associated with a longer period without skeletal events.
评估单剂量放射治疗(8 Gy与6 Gy)联合唑来膦酸对骨转移癌患者疼痛的治疗效果;生活质量、骨相关事件发生时间及功能状态。
来自22家西班牙医院的139例患者被随机分为:A组,给予单剂量8 Gy + 唑来膦酸(4 mg静脉注射,15分钟输注);B组,给予单剂量6 Gy + 唑来膦酸(4 mg静脉注射,15分钟输注)。主要变量为疼痛,通过视觉模拟疼痛量表(VAS)在仰卧位、坐位和站立位进行评估。
共有118例患者纳入意向性分析(A组67例,B组51例)。最常见的原发性肿瘤为肺癌(29.66%)、前列腺癌(22.03%)和乳腺癌(21.19%)。按方案分析60例患者,A组34例,B组26例。在所有三个体位的VAS疼痛评分均有改善。A组事件发生的平均时间长于B组(122天对81.62天,p = 0.0211)。A组功能状态改善,两组生活质量均改善。
两组在仰卧位、坐位和站立位均达到相似的疼痛控制水平。两组生活质量也均有改善。然而,较高剂量(8 Gy)联合唑来膦酸与更长的无骨相关事件时间相关。